Home Antibody All anti-FBXO43 antibodies
Also for FBXO43 (NM_001029860)
|This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to a region approximately 60 residues downstream of the amino terminal end of human Fbp5B protein. Human Fbp5B-2, 466 aa, predicted MW 51.3 kDa|
|human, mouse, rat, chimpanzee
||ELISA: 1:10,000 - 1:50,000, WB: 1:500 - 1:3,000, IP: 1:100
|0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2|
|Fbp5B (also called F-Box protein 43 or Fbx043) is a relatively new member of the F-box protein family that is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class.
|Homo sapiens F-box protein 43 (FBXO43), transcript variant 2|
|EMI2; ERP1; FBX43|
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot using affinity purified anti-Fbp5B antibody. Panels A and B show two identical membranes containing marker, in vitro translated Fbp5b (Fbp5b ivt), and a whole cell extract from 293T cells loaded in duplicate). Panel A shows antibody reactivity. Panel B shows antibody reactivity after first pre-incubating the antibody with the immunizing peptide. This pre-incubation greatly diminishes specific band recognition. Peptide inhibition completely removes the in vitro translated band and greatly reduces the endogenous band from 293T cells. When this experiment was repeated using a mock in vitro translation, no band was detected (data not shown). Personal Communication, Daniele Guardavaccaro, NYU Cancer Institute